Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...
Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...
Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...
In keeping with its 2027 cost-cutting deadline, Merck & Co. announced another round of layoffs at its global headquarters in Rahway, New Jersey. | Merck continues sweeping staff reductions, laying off ...
On Wednesday, BioMarin unveiled detailed results from the phase 3 CANOPY-HCH-3 trial assessing Voxzogo in children with hypochondroplasia (HCH), a milder form of achondroplasia, where the company ...
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar ...
With the help of AI, AstraZeneca’s three-in-one inhaler Breztri has a new furry mascot to help it stand tall over the crowded ...
GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results